Month: March 2025

IBA reports solid Full Year 2024 results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Read the entire full year 2024 results press release hereLouvain-la-Neuve, Belgium, 20 March 2025 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2024 financial year.Record-high revenue and return to profitability in 2024 driven by well-executed backlog conversionNet sales rose 7% to €498.2 million1, with Other Accelerators increasing by 18% Gross margin improvement to 33.3% vs. 28.8% in 2023, driven by higher share of Other Accelerators and margin improvement in Proton Therapy REBIT at €17.3 million, up 170% (FY 2023: €6.4 million) mostly from well-executed backlog conversion, especially in Other Accelerators (+€11 million REBIT YoY), including continued investments in future growth and R&D innovation Net result of €9.3 million...

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private placement and 67% reduction in operating cash burn Substantial clinical and regulatory progress in 2024; further data readouts, product approvals and label extensions anticipated in 2025 2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burnSaint-Herblain (France), March 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its consolidated financial results for the year ended December 31, 2024 and provided key corporate updates and guidance for its future results. The consolidated financial...

VEON to Proceed with USD 35 Million Share Buyback

Written by Customer Service on March 20, 2025. Posted in Public Companies.

VEON to Proceed with USD 35 Million Share Buyback Announcement marks second phase of USD 100 million share buyback program announced on August 1, 2024 Dubai, March 20, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), announces that it will shortly commence the second phase of its previously announced share buyback program with respect to the Company’s American Depositary Shares (“ADS”). This second phase of the buyback will be in the amount of up to USD 35 million. The second phase of the share buyback program is being launched after completion of the USD 30 million first phase on January 27, 2025. VEON’s Board of Directors approved a share buyback program of up to USD 100 million on July 31, 2024. The Company continues to believe that its ADSs are undervalued relative to its operational performance...

VEON FY24 and 4Q24 Trading Update: Strong Delivery in 2024, Digital Services Driving Growth

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

VEON FY24 and 4Q24 Trading Update: Strong Delivery in 2024, Digital Services Driving Growth Dubai, March 20, 2025, 10:10 GST VEON FY24 HighlightsTotal revenue growth of 8.3% YoY to USD 4,004 million (+14.6% YoY in underlying local currency terms) EBITDA growth of 4.9% YoY to USD 1,691 million (+12.0% YoY in underlying local currency terms) Direct digital revenue growth of 63.0% YoY to USD 460 million (+64.1% YoY in local currency terms), representing 11.5% of revenues for the full year Total cash and cash equivalents and deposits of USD 1,691 million, with USD 481 million at headquarters (“HQ”); and gross debt at USD 4.4 billion (decreased by USD 311 million YoY), with net debt excluding lease liabilities at USD 1.9 billion Equity Free Cash Flow of USD 403 million, Capex of USD 826 millionVEON Ltd. (Nasdaq: VEON), a global digital...

Enerflex Ltd. Announces Leadership Transition

Written by Customer Service on March 20, 2025. Posted in Public Companies.

MARC ROSSITER STEPS DOWN AS PRESIDENT, CEO, AND DIRECTOR PREET DHINDSA NAMED INTERIM CEO REAFFIRMS 2025 OUTLOOK AND CONCURRENTLY ANNOUNCES EXPANSION OF DIRECT SHAREHOLDER RETURNS CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today announced that Marc Rossiter has stepped down as President, CEO, and Director, effective immediately. Preet Dhindsa, Enerflex’s current Senior Vice President and CFO, will serve as Interim Chief Executive Officer. Mr. Dhindsa joined Enerflex in October 2023 and is a seasoned executive with more than 25 years of experience, primarily in the energy and financial services industries. Joe Ladouceur, Vice President Treasury, Tax & Insurance, will serve as Interim CFO. The Board is undertaking a comprehensive search to identify the...

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Written by Customer Service on March 20, 2025. Posted in Public Companies.

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on March 21, 2025,...

Enerflex Ltd. Announces Normal Course Issuer Bid

Written by Customer Service on March 20, 2025. Posted in Public Companies.

CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today announced Board approval to implement a Normal Course Issuer Bid (“NCIB”). The Company intends to make an application to the Toronto Stock Exchange (“TSX”) to implement a NCIB that would permit the Company to purchase for cancellation, through the facilities of the TSX, alternative Canadian trading systems or the New York Stock Exchange, common shares representing up to 5% of the public float over a period of twelve months. The NCIB is subject to acceptance by the TSX and will be conducted in accordance with the rules and policies of the TSX and applicable securities laws. Preet Dhindsa, Enerflex’s Interim CEO stated, “With the Company operating within its target leverage range, Enerflex is positioned...

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Written by Customer Service on March 20, 2025. Posted in Public Companies.

YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner. About OptinoseOptinose is a specialty pharmaceutical company focused on serving the needs of patients cared...

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Written by Customer Service on March 20, 2025. Posted in Mergers And Acquisitions.

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market Acquisition advances Paratek’s vision to become a multi-product company focused on innovative specialty therapies Total transaction value of up to ~$330 million Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose’s closing trading price on March 19, 2025BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, including its approved product XHANCE® (fluticasone propionate). The transaction value is up to $330 million,...

Pieridae Releases Q4 and Full Year 2024 Financial & Operating Results and 2024 Reserves

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Achieved Pivotal Strategic Milestones While Reducing Costs, Growing Third-Party Volumes, and Proactively Managing Production NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORDISSEMINATION IN UNITED STATES CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) — Pieridae Energy Limited (“Pieridae” or the “Company”) (TSX: PEA) announces the release of its fourth quarter and full year 2024 financial and operating results and year-end reserves. Pieridae generated Net Operating Income1 (“NOI”) of $64.6 million and produced 27,763 boe/d (84% natural gas) during 2024. The Company posted Q4 NOI of $13.7 million and production of 22,568 boe/d, while 2024 exit production was approximately 25,558 boe/d. The Company also filed its Annual Information Form (“AIF”) for the year ended December 31, 2024, including the 2024 independent...

Month: March 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals